Bacteriophage endolysins and novel lipid-degrading proteins as a treatment for Rhodococcus equi infections in foals

  Rhodococcus equi (Req) is responsible for severe respiratory disease of foals with a major economic impact on the equine industry, and can be endemic on stud farms. In foals under 6 months of age, this bacterial disease manifests as pneumonia, with 30% mortality amongst antibiotic-treated foals (70-80% mortality in untreated cases). Furthermore, foals that recover from the disease are less likely to race as adults. In addition to potential life-threatening side-effects observed with rifampin/antibiotic treatment, there is increasing prevalence of antibiotic resistance. Together with the lack of effective commercial vaccines, this highlights the urgency for novel tools as alternatives, or as a complement, to antibiotics.

  • Start Date:

    1 October 2018

  • End Date:

    30 June 2019

  • Activity Type:

    Externally Funded Research

  • Funder:

    Horserace Betting Levy Board

  • Value:

    £10832

Project Team